TheraRadar
Data updated: May 26, 2026

DUREZOL (difluprednate)

Pain Approved 2008-06-23

Durezol is a corticosteroid used to manage pain and swelling in patients who have recently undergone eye surgery. It also treats endogenous anterior uveitis, a condition involving inflammation inside the eye. This medication helps reduce the physical symptoms of inflammation to improve patient comfort and recovery.

Source: FDA Label • Novartis

How DUREZOL Works

This medication works by inducing specific inhibitory proteins that block the release of arachidonic acid, a precursor to inflammatory triggers like prostaglandins and leukotrienes. By preventing the production of these mediators, the drug suppresses swelling, capillary dilation, and the formation of scar tissue.

3
Indications
--
Phase 3 Trials
2
Priority Reviews
17
Years on Market

Details

Status
Prescription
First Approved
2008-06-23
Routes
OPHTHALMIC
Dosage Forms
EMULSION

Companies

Active Ingredient: DIFLUPREDNATE

DUREZOL Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2008 to 2025 · 2 indication expansions
Oct 2025 SUPPL
Label · Labeling
Jul 2025 SUPPL
Label · Labeling
Jul 2016 SUPPL
Label · Labeling

What DUREZOL Treats

3 indications

DUREZOL is approved for 3 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Inflammation
  • Pain
  • Uveitis
Source: FDA Label

DUREZOL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 12 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DUREZOL

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DIFLUPREDNATE
DIFLUPREDNATE
3 shared
Viatris
Shared indications:
ACUVAIL
KETOROLAC TROMETHAMINE
2 shared
AbbVie
Shared indications:
BYQLOVI
CLOBETASOL PROPIONATE
2 shared
HARROW EYE
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT01939691 MEND 18-24978 Ph 4 terminated Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
NCT00616993 ST-601-004 Ph 3 completed Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DUREZOL FDA Label Details

Indications & Usage

FDA Label (PDF)

DUREZOL is indicated for the treatment of Inflammation; Pain; Uveitis.

Track DUREZOL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.